Such approaches appear to have limited anti-tumor efficacy unless immune checkpoint inhibitors (Nivolumab, anti-PD-1 mAb; Ipilimumab, anti-CTLA-4 mAb) are used in reactivating residential T cells. The gene discussed is CTLA4; the disease is neoplasm.